MonoGen, Inc.

MonoGen, Inc.

April 10, 2007 08:45 ET

MonoGen Installs MonoPrep Liquid-Based Preparation System at The Johns Hopkins Hospital

MONTREAL, QUEBEC--(CCNMatthews - April 10, 2007) - This Press Release is Not for Distribution in the United States

MonoGen, Inc. ("Corporation")(TSX:MOG) today announced that it has entered into an agreement with The Johns Hopkins Hospital (JHH) to evaluate the MonoPrep® liquid-based preparation system for non-gynecological applications during a 6-month trial period. The MonoPrep processor has been installed at JHH under the supervision of the Director of Cytopathology, and the training of laboratory personnel and the processing of research specimens has begun.

"Evaluation of our MonoPrep products at the Johns Hopkins Hospital is an important priority to MonoGen during our pre-launch phase because of its potential to demonstrate the broad utility of MonoPrep for non-gynecological specimen processing applications in cytopathology laboratories," reported Jim Cureton, Vice President of Sales and Marketing at MonoGen. "We are pleased with the ease of training and the enthusiastic initial responses we are encountering at this early adopter site internationally recognized for its standard of excellence in medical education, research and clinical care," cited Peter Kilner, Director of Client Services at MonoGen.

About MonoGen, Inc.

With operational headquarters in the United States (Greater Chicago area), MonoGen is a medical device company developing an integrated suite of fully automated devices (the SAVANT LABORATORY SYSTEM™) for anatomic and molecular pathology laboratories. The SAVANT LABORATORY SYSTEM™ is being designed to automate processes performed by clinical laboratories to reduce their costs, increase throughput, and improve the quality and consistency of results.

The common shares of the Corporation are listed for trading on the Toronto Stock Exchange under the trading symbol "MOG".

Forward-Looking Statements

This press release is not for distribution in the United States.

This press release contains statements that are forward-looking in nature. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements.

Forward-looking statements are based on the Corporation's beliefs and assumptions based on information available at the time the assumption was made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments, relating to the Corporation. By its nature, such forward-looking information is subject to various risks and uncertainties which could cause the Corporation's actual results and experience to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to MonoGen's ability to raise additional capital, MonoGen's ability to execute its business plan while maintaining at all times its various regulatory approvals, the performance of its strategic partners including the performance of Cardinal Health in the commercialization of the Corporation's products in the marketplace and the competitive response from existing and potential competitors. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document, and the Corporation undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contact Information

  • MonoGen, Inc.
    Norman J. Pressman, Ph.D.
    Executive Chairman and Chief Scientific Officer
    847-758-4202 (FAX)